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Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related mortality in the world. The majority of
NSCLC patients are diagnosed with advanced-stage dis-
ease and almost all except a tiny minority will develop
incurable metastatic disease. The standard of care for such
patients with a good performance status (PS) is currently
platinum based chemotherapy, which can offer palliation
of symptoms but only modest survival improvement [1-3].
Nearly all patients who receive systemic therapy for
advanced-metastatic NSCLC will eventually relapse [4].
This is an unquestionable reality. Physicians who deal with
medical management of NSCLC patients who failed first
line therapy are often puzzled with three key questions: if,
what, and whom, to offer a second line therapy. Existing
evidence is unfortunately weak, if not confusing, to
address such issues. It is therefore apparent that for opti-
mal medical management of these patients we need mole-
cular and/or clinical biomarkers to safe-guide therapeutic
decisions.
Randomized clinical trials have shown that second-line
chemotherapy in NSCLC patients who failed or relapsed
first-line therapy, can offer modest and marginal survival
benefits at the cost of considerable toxicity. Yet patients
enrolled in such studies were not quite representative of
this group of patients [5]. Treatment options available
for previously treated advanced-metastatic NSCLC are
single agent docetaxel, pemetrexed, and epidermal
growth factor receptor inhibitors (erlotinib and gefitinib)
[6]. It should be stressed herein that only single-agent
therapies have been approved and are recommended for
clinical use in this clinical setting. Combination che-
motherapy failed to show survival benefits when com-
pared with single agent treatment in the clinical setting
of second line chemotherapy but increased toxicity [7].
Results were also disappointing when chemotherapy was
combined with anti-VEGF antibody bevacizumab [8].
Approximately 30% of patients with advanced-
metastatic NSCLC will also receive second-line che-
motherapy [9]. It is therefore obvious that we need
biomarkers to help us select patients who have chances to
get benefit from therapy and pick the best therapeutic
option for each individual. Several investigators have tried
to profile NSCLC patients who can tolerate second line
chemotherapy [10,11]. Treatment tolerability is always a
significant parameter for patients who are offered palliative
therapy. In advanced NSCLC, patients with a poor perfor-
mance status (PS 2 and worse) have shown to fare poorly
to platinum-based doublets even when treatment is given
upfront [12]. Although newer agents have been tested in
doublets or in combination with novel platinum com-
pounds [13], no benefit was observed when compared to
single agent chemotherapy [7]. Currently it is recom-
mended that such patients should be offered single-agent
chemotherapy to low the risk of unwanted toxicity, which
is expected high in such cases [6,7]. Moreover, there is no
evidence to support second-line treatment of patients with
poor performance status [14].
A recent analysis, which included data from 1239
patients, demonstrated that prognosis is significantly
influenced by gender (worse in males), PS, tumor histol-
ogy (worse in squamous and other histology versus ade-
nocarcinoma), stage (worse in IV versus IIIB), type of
previous treatment (worse for patients pretreated with
platinum) and response to first-line (worse for patients
not obtaining objective response). The authors devised a
summary index (score) that could discriminate patients
into three categories according to probability of survival
[11]. However, prospective studies aiming to identify
patients with relapsed advanced-metastatic NSCLC who
might be benefited of second-line chemotherapy are sur-
prisingly missing. The paper of Belbaraka et al. [15],
from Centre Léon Bérard, Lyon, France, stresses this
issue in a prospective way. The authors identified poor
PS as the primary indicator for failure to second line
chemotherapy. Despite its limitations, (i.e. small number
of patients, heterogeneity of chemotherapy administered
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and lack of quality-of-life data), this prospective study
showed that poor PS should make treating physicians
reluctant in advising second-line chemotherapy for
patients with relapsed NSCLC [15].
Nevertheless it should be noticed that chemotherapy
is not the only systemic therapy available for NSCLC
patients today. Small molecule inhibitors of cancer-asso-
ciated disordered epidermal growth factor receptor
(EGFR) are now approved for NSCLC patients with
EGFR mutated tumors [16]. We have previously pro-
claimed that personalized therapeutic management
based on molecular predictors should be considered the
most proper approach in terms of good clinical practice,
in the era of cancer targeted therapy [17]. Interestingly,
it has been shown that such therapies can substantially
benefit patients if only offered to molecularly defined
target populations irrespectively of previous therapy.
A recent study showed that gefitinib is equally effective
in patients affected by EGFR mutated tumors in chemo-
naive patients and in chemotherapy-treated patients
[18-20].
Whether we should treat patients who relapse after
second line chemotherapy is another issue [21]. Massar-
elli et al. conducted a retrospective analysis of over 700
patients who had received two or more prior che-
motherapy regimens for recurrent-metastatic NSCLC.
They found that median survival and response rates
decreased steadily with each subsequent regimen. The
objective responses became infrequent and of short
duration and toxicities increased considerable [22].
Understandably, the vast majority of patients who
receive second-line therapy are not expected to qualify
for a third-line treatment, because of compromised
organ functions, clinical deterioration and development
of resistance to chemotherapeutics. Besides, we lack
phase III data to support routine use of chemotherapy
in the third-line setting [3]. For these patients, suppor-
tive care is the only reasonable option, in addition to
experimental treatments in clinical trials [3].
Symptom palliation and Quality of Life are primary
goals of therapy for patients with advanced-metastatic
NSCLC upon tumor relapse. Therefore, «gentle» effec-
tive therapies, as are weekly and metronomic regimens
should rather be favored in cases of relapsed NSCLC
patients who are at risk of severe toxicity [23,24].
Finally, when making treatment decisions for patients
with relapsed advanced NSCLC we, physicians, should
always be simple and wise in our approach. As a rule of
thumb, we should preferably opt a targeted or gentle
therapy and should let patient’s performance status
remind us that we may try rechallenge the tumor but
not the patient.
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